Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Variable n/mean Percentage/SD
Sex   
 Male 27 67.5
Age, year 61.5 12.9
Age   
 < 65 years 18 45.0
 ≥ 65 years 22 55.0
Dialysis method   
 Hemodialysis 15 38.5
 Hemodiafiltration 24 61.5
Dialysis history   
 < 1 year 3 7.5
 ≥ 1 and < 3 years 7 17.5
 ≥ 3 years 30 75.0
Primary disease of dialysis   
 Chronic glomerulonephritisa 16 40.0
 Diabetic nephropathy 13 32.5
 Nephrosclerosis 7 17.5
 Polycystic kidney 1 2.5
 Unknown 3 7.5
Complication   
 Hypertension 33 82.5
 Diabetes mellitus 16 40.0
 Dyslipidaemia 12 30.0
Prior hyperphosphatemia drug   
 Calcium carbonate 10 25.0
 Calcium carbonate + lanthanum carbonate hydrate 7 17.5
 Calcium carbonate + sevelamer hydrochloride 3 7.5
 Calcium carbonate + bixalomer 3 7.5
 Calcium carbonate + iron(III) citrate hydrate 2 5.0
 Calcium carbonate + lanthanum carbonate hydrate + iron(III) citrate hydrate 1 2.5
 Lanthanum carbonate hydrate 9 22.5
 Lanthanum carbonate hydrate + iron(III) citrate hydrate 1 2.5
 Bixalomer 4 10.0
Daily dose of lanthanum carbonate hydrate, mg 1500.0 500.0
ESAsb administration 38 95.0
Cumulative dose of ESAs, IUc 25,315.8 18,207.7
Intravenous iron administration 5 12.5
Cumulative dose of intravenous iron, mg 160.0 0.0
  1. The values are mean (standard deviation) or n (%). Data for the 4 weeks before the start of the study shown for ESAs and intravenous iron
  2. aIncluding IgA nephropathy
  3. bErythropoiesis-stimulating agents
  4. cInternational unit